PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportshiv
MeSH D006678 - hiv
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006678: 
Hiv
$
Success rate
D015497:Hiv-1
$
Success rate
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2018-11-09   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2017-06-08   
Tenofovir disoproxil Tenofovir Disoproxil  2015-03-18   
MylanTenofovir disoproxil, Lamivudine Cimduo  2018-02-28   
Emtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan  2017-09-05   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2018-04-09   
Emtricitabine, Tenofovir disoproxil Emtricitabine/Tenofovir disoproxil Mylan  2016-12-16   
Tenofovir disoproxil, Efavirenz, Lamivudine Symfi  2018-03-22   
Tenofovir disoproxil, Efavirenz, Lamivudine Symfi Lo  2018-02-05   
Tenofovir disoproxil Tenofovir Disoproxil  2018-11-27   
Tenofovir disoproxil Tenofovir disoproxil Mylan  2016-12-08   
CiplaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2019-06-03   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2021-04-02   
Tenofovir disoproxil Tenofovir Disoproxil  2018-01-26   
Chartwell PharmaceuticalsEmtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2021-06-04   
Tenofovir disoproxil Tenofovir Disoproxil  2018-07-26   
Tenofovir disoproxil, Lamivudine Temixys  2018-11-16   
Merck Sharp & DohmeDoravirine, Tenofovir disoproxil, Lamivudine Delstrigo 2031-10-07 2018-08-30 $100 M Q1/23-Q1/24 
Aurobindo PharmaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2018-09-04   
Tenofovir disoproxil, Efavirenz, Lamivudine Efavirenz, Lamivudine Tenofovir Disoproxil  2018-08-15   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2018-01-26   
Tenofovir disoproxil, Lamivudine Lamivudine Tenofovir Disoproxil  2018-05-15   
Tenofovir disoproxil Tenofovir Disoproxil  2018-01-26   
Zydus TherapeuticsEmtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2020-02-28   
ApotexEmtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2021-06-16   
HeteroEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2022-01-24   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2021-10-07   
Tenofovir disoproxil Tenofovir Disoproxil  2018-01-26   
Macleods PharmaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2021-09-13   
Tenofovir disoproxil, Efavirenz, Lamivudine Efavirenz, Lamivudine Tenofovir Disoproxil  2019-03-15   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2020-05-15   
Tenofovir disoproxil Tenofovir Disoproxil  2018-01-26   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
72%
71/99
Phase 2
46%
54/117
Phase 3
47%
37/78
Approved: 0Overall Success rate: 16%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mylan
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use